NCT04400929View on ClinicalTrials.gov

Using GM-CSF as a Host Directed Therapeutic Against COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

January 26, 2022

Study Completion Date

February 4, 2022

Conditions
COVIDSars-CoV2ARDS, Human
Interventions
DRUG

Sargramostim

Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.

OTHER

Normal Saline 0.9%

IV normal saline 0.9% for 5 days

Trial Locations (1)

Unknown

Singapore General Hospital, Singapore

All Listed Sponsors
lead

Singapore General Hospital

OTHER

NCT04400929 - Using GM-CSF as a Host Directed Therapeutic Against COVID-19 | Biotech Hunter | Biotech Hunter